In Studies 2 (NCT#03548935), 3 (NCT#03552757), and 4 (NCT#03611582), WEGOVY or matching placebo was escalated to 2.4 mg subcutaneous weekly during a 16-week period followed by 52 weeks on maintenance dose
These providers maintain independent medical judgment while utilizing Ro's technology infrastructure for service delivery, patient communication, and care coordination
Furthermore, reconstitution of wildtype (100) or LDL receptor deficient mice( Ldlr -/- ) (101) with Apoe -/- bone marrow accelerates atherosclerotic lesion development without affecting plasma cholesterol levels, demonstrating an atheroprotective role for macrophage apoE
But there can be some differences in the frequency and intensity of some due to the dual action mechanism and higher dosage levels for Mounjaro/Zepbound
To our knowledge, there are no studies that have investigated the role of VNS in the context of neuroinflammation and epilepsy